EVMN · Insider Trading
Evommune, Inc.
Every open-market purchase and sale reported by EVMN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Luis C. Pena | President & CEO | A | +1,115 | +$7.83K |
| 2026-07-10 | Kyle Carver | Chief Financial Officer | Buy | +1,000 | +$13.26K |
| 2026-07-08 | Arthur S Kirsch | Director | Buy | +10,000 | +$133.00K |
| 2026-06-24 | Luis C. Pena | President & CEO | Sell | −7,438 | −$168.92K |
| 2026-06-24 | Jeegar Pravinkumar Patel | Chief Scientific Officer | MIXED | — | −$27.77K |
| 2026-06-24 | Janice Suzann Drew | Chief of Dev. Operations | MIXED | — | −$389.54K |
| 2026-06-03 | Arthur S Kirsch | Director | A | +15,673 deriv. | — |
| 2026-06-03 | Jeegar Pravinkumar Patel | Chief Scientific Officer | MIXED | −3,175 | −$327.58K |
| 2026-06-03 | Luis C. Pena | President & CEO | Sell | −16,787 | −$381.74K |
| 2026-06-03 | David E Cohen | Director | Sell | −6,056 | −$123.09K |
| 2026-06-03 | Benjamin F McGraw III | Director | A | +15,673 deriv. | — |
| 2026-06-01 | Kyle Carver | Chief Financial Officer | MIXED | −3,175 | −$370.27K |
| 2026-06-01 | Gregory S. Moss | Chief Business & Legal Officer | MIXED | — | −$300.39K |
| 2026-04-17 | Janice Suzann Drew | Chief of Dev. Operations | A | +73,892 deriv. | — |
| 2026-04-17 | Luis C. Pena | President & CEO | A | +291,420 deriv. | — |
| 2026-04-17 | Eugene Bauer | Chief Medical Officer | A | +51,117 deriv. | — |
| 2026-04-17 | Gregory S. Moss | Chief Business & Legal Officer | A | +115,279 deriv. | — |
| 2026-04-17 | Jeegar Pravinkumar Patel | Chief Scientific Officer | A | +69,315 deriv. | — |
| 2026-04-17 | Kyle Carver | Chief Financial Officer | A | +98,946 deriv. | — |
| 2026-02-19 | 7 Cooperative UA LSP | Director | A | +358,680 | +$10.00M |
| 2026-02-18 | Weegen Felice Isabel Verduyn-van | Director | A | +358,680 | +$10.00M |
| 2026-02-17 | RA Capital Nexus Fund III, L.P. | Director | A | +35,868 | +$1000.00K |
| 2025-12-22 | Robert Lorne Hopfner | Director | Buy | +1,000 | +$17.35K |
| 2025-12-19 | Eugene Bauer | Chief Medical Officer | A | +100,000 deriv. | — |
| 2025-12-11 | Jeegar Pravinkumar Patel | Chief Scientific Officer | F | −7,513 | −$134.03K |
| 2025-12-11 | Janice Suzann Drew | EVP, Operations | F | −5,074 | −$90.52K |
| 2025-12-11 | Gregory S. Moss | Chief Business & Legal Officer | F | −13,624 | −$243.05K |
| 2025-12-11 | Luis C. Pena | President & CEO | F | −28,138 | −$501.98K |
| 2025-12-11 | Kyle Carver | Chief Financial Officer | F | −13,290 | −$237.09K |
| 2025-12-11 | Eugene Bauer | Chief Medical Officer | F | −1,478 | −$26.37K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| 7 Cooperative UA LSP | Director | 5,288,313 | $31.94M |
| Weegen Felice Isabel Verduyn-van | Director | 5,288,313 | $31.94M |
| RA Capital Nexus Fund III, L.P. | Director | 784,345 | $4.74M |
| Luis C. Pena | President & CEO | 631,573 | $3.81M |
| Robert Lorne Hopfner | Director | 294,502 | $1.78M |
| Eugene Bauer | Chief Medical Officer | 270,818 | $1.64M |
| Janice Suzann Drew | Chief of Dev. Operations | 87,794 | $530.28K |
| Gregory S. Moss | Chief Business & Legal Officer | 64,010 | $386.62K |
| Kyle Carver | Chief Financial Officer | 60,335 | $364.42K |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | 46,403 | $280.27K |
| David E Cohen | Director | 18,209 | $109.98K |
| Arthur S Kirsch | Director | 10,000 | $60.40K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EVMN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.